Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial

Gynecologic Oncology

Volumn 113, Issue 1, 2009, Pages 16-20

  Kurtz, J E ^a   Hardy Bessard, A C ^b   Deslandres, M ^c   Lavau Denes, S ^d   Largillier, R ^e   Roemer Becuwe, C ^f   Weber, B ^g   Guillemet, C ^h   Paraiso, D ⁱ   Pujade Lauraine, E ^j  

^a HÔPITAL CIVIL   (France)

^b Clinique Armoricaine de Radiologie   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d DUPUYTREN UNIVERSITY HOSPITAL   (France)

^e CENTRE ANTOINE LACASSAGNE   (France)

^f Centre d'Oncologie de Gentilly   (France)

^g CENTRE ALEXIS VAUTRIN   (France)

^h CENTRE HENRI BECQUEREL   (France)

ⁱ Centre Hospitalier de l'Agglomeration Montargeoise   (France)

^j UNIVERSITÉ PARIS DESCARTES   (France)

more..

Author keywords

Advanced cervical cancer; Cetuximab; Cisplatin; Phase II; Topotecan

Indexed keywords

ANTIEMETIC AGENT; BILIRUBIN; CETUXIMAB; CISPLATIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADULT; ADVANCED CANCER; ALOPECIA; ANEMIA; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; LUNG EMBOLISM; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN MANIFESTATION; SQUAMOUS CELL CARCINOMA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LOCALIZATION; UTERINE CERVIX ADENOCARCINOMA; UTERINE CERVIX CANCER;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; MIDDLE AGED; TOPOTECAN; UTERINE CERVICAL NEOPLASMS;

EID: 62749156047     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.12.040     Document Type: Article

References (16)

1. Long H.J., Bundy B.N., Grendys E.C., et al. Randomized phase III of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J. Clin. Oncol. 23 (2005) 4626-4633
2. Yarden Y., and Ullrich A. Growth factor receptor tyrosine kinases. Annu. Rev. Biochem. 57 (1988) 443-478
3. Oh M.J., Choi J.H., Kim I.H., et al. Detection of epidermal growth factor receptor in the serum of patients with cervical carcinoma. Clin. Cancer Res. 6 (2000) 4760-4763
4. Hale R.J., Buckley C.H., Gullick W.J., Fox H., Williams J., and Wilcox F.L. Prognostic value of epidermal growth factor receptor expression in cervical carcinoma. J. Clin. Pathol. 46 (1993) 149-153
5. Kersemaekers A.M.F., Fleuren G.J., Kenter G.G., et al. Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. Clin. Cancer Res. 5 (1999) 577-586
6. Kristensen G.B., Holm R., Abeler V.M., and Trope C.G. Evaluation of the prognostic significance of cathepsin D, epidermal growth factor receptor, and c-erbB-2 in early cervical squamous cell carcinoma: an immunohistochemical study. Cancer 78 (1996) 433-440
7. Kim J.W., Kim Y.T., Kim D.K., Song C.H., and Lee J.W. Expression of epidermal growth factor receptor in carcinoma of the cervix. Gynecol. Oncol. 60 (1996) 283-287
8. Scambia G., Ferrandina G., Distefano M., D'Agostino G., Benedetti-Panici P., and Mancuso S. Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer. Cancer Lett. 123 (1998) 135-139
9. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354 (2006) 567-578
10. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 92 (2000) 205-216
11. Vermorken J.B., Trigo J., Hitt R., et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J. Clin. Oncol. 25 (2007) 2171-2177
12. Burtness B., Goldwasser M.A., Flood W., Mattar B., and Forastiere A.A. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J. Clin. Oncol. 23 (2005) 8646-8654
13. Ciardiello F., Bianco R., Damiano V., et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal C-225. Clin. Cancer Res. 5 (1999) 909-916
14. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med. 351 (2004) 337-345
15. Rosell R., Robinet G., Szczesna A., et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann. Oncol. 19 (2008) 362-369
16. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N. Engl. J. Med. 359 (2008) 1116-1127